Asia

Novartis bets $2bn on biologics as Xolair patents fade
27 March 2026   The Swiss pharma giant targets next-generation anti-IgE biologics as it looks to extend its dominance in the market.

Latest Features

Asia
Hui Zhuang of CCPIT Patent and Trademark Law Office discusses several strategies to increase the chance of pharmaceutical or food trademarks that include ingredients being registered.
Biotechnology
Agreeing to a dispute resolution mechanism in an international joint venture requires forward thinking, say Jens Petry and Tom Gassmann, Squire Patton Boggs.
Asia
Five cases in which preliminary injunctions were granted are examined by Takanori Abe of Abe & Partners.
Asia
A Korean district court has applied a landmark ruling in a complicated vaccine dispute involving Pfizer, explain Young Kim, Yu-Seog WON, In Hwan Kim, and Amy Oh of Kim & Chang.
Asia
Amid worldwide interest, India could position itself as a global hub for a desperately needed technology, say Kavita Arora and Shaivya Dhawan of K&S Partners.
Asia
The Tokyo District Court judgment on patent infringement and question of territoriality is game-changing, says Takanori Abe of Abe & Partners.
Africa
The global pandemic has increased collaboration and a new wave of disputes is likely. Arbitration is well placed to help, argue Kate Davies McGill, Gaela Gehring Flores and Paul Keller of Allen & Overy
Asia
Recent changes to patent law in China sees registration, review and litigation fall in line with established international IP systems, say Venable partners Keith Haddaway and Christopher Loh.
All features


More News

18 February 2026   The science and technology conglomerate’s big diagnostics bet comes with monitoring technology, an AI-powered product pipeline, and a litigation history that has kept Silicon Valley’s biggest player on the back foot.
5 February 2026   The British-Swedish pharma giant pays $1.2 billion upfront for access to next-generation weight-loss treatment as China patent cliff changes the market.
23 January 2026   Just one pharma company is recognised in a report that lists the most world's most inventive countries and companies.
20 January 2026   Magic Circle and major US firm among dealmakers who worked on the licensing agreement for a bispecific antibody candidate, marking another significant outbound licensing deal from China’s biopharma sector.
6 January 2026   Danish pharma giant notches an important victory in a huge market for semaglutide, but faces a patent cliff and mounting challenges across India, Canada and the US.
4 December 2025   The Delhi High Court has denied an injunction against an Indian generic manufacturer, finding credible challenges to the validity of Novo's semaglutide patent—flagging concerns over obviousness, double patenting, and evergreening.
7 November 2025   Sister title WIPR’s China Patent Rankings detail the firms and individuals most capable of handling patent matters in the country, from litigators with winning streaks to global strategists.
More news